BR112014014913A2 - mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa - Google Patents
mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativaInfo
- Publication number
- BR112014014913A2 BR112014014913A2 BR112014014913A BR112014014913A BR112014014913A2 BR 112014014913 A2 BR112014014913 A2 BR 112014014913A2 BR 112014014913 A BR112014014913 A BR 112014014913A BR 112014014913 A BR112014014913 A BR 112014014913A BR 112014014913 A2 BR112014014913 A2 BR 112014014913A2
- Authority
- BR
- Brazil
- Prior art keywords
- ngf
- prongf mutant
- biologically active
- prongf
- active human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa a presente invenção refere-se a um mutante prongf e a utilização do mesmo, em particular, a utilização de um mutante prongf humano para a produção de beta-ngf. a presente invenção descreve um método de preparação de uma beta-ngf humana ativa biologicamente a partir de um mutante prongf insolúvel inativo. um mutante prongf da invenção é substituído por qualquer aminoácido, mas não arg ou lys no local de clivagem da protease nativa r1sk3r4, pelo menos nas posições r1 e k3 correspondentes às posições 101 e 103 da sequência de prongf tipo selvagem humana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11194208 | 2011-12-19 | ||
| EP11194208.2 | 2011-12-19 | ||
| PCT/EP2012/076251 WO2013092776A1 (en) | 2011-12-19 | 2012-12-19 | Novel prongf mutants and uses thereof in the production of beta-ngf |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014014913A2 true BR112014014913A2 (pt) | 2017-06-13 |
| BR112014014913B1 BR112014014913B1 (pt) | 2020-12-01 |
Family
ID=47428641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014913-5A BR112014014913B1 (pt) | 2011-12-19 | 2012-12-19 | mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9617322B2 (pt) |
| EP (2) | EP2672984B1 (pt) |
| JP (4) | JP6039146B2 (pt) |
| KR (2) | KR20160120788A (pt) |
| CN (2) | CN104203264B (pt) |
| AU (1) | AU2012357052B2 (pt) |
| BR (1) | BR112014014913B1 (pt) |
| CA (1) | CA2859262C (pt) |
| CY (2) | CY1117016T1 (pt) |
| DK (2) | DK2672984T3 (pt) |
| EA (1) | EA031333B1 (pt) |
| ES (2) | ES2657344T3 (pt) |
| HK (1) | HK1202055A1 (pt) |
| HR (2) | HRP20150900T1 (pt) |
| HU (2) | HUE036265T2 (pt) |
| IL (1) | IL233137A0 (pt) |
| LT (1) | LT2907521T (pt) |
| MX (2) | MX353074B (pt) |
| NO (1) | NO2907521T3 (pt) |
| PL (2) | PL2672984T3 (pt) |
| PT (2) | PT2672984E (pt) |
| RS (2) | RS56893B1 (pt) |
| SG (2) | SG11201402585PA (pt) |
| SI (2) | SI2672984T1 (pt) |
| SM (1) | SMT201500201B (pt) |
| TR (1) | TR201802360T4 (pt) |
| WO (1) | WO2013092776A1 (pt) |
| ZA (1) | ZA201403753B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2672984E (pt) | 2011-12-19 | 2015-10-01 | Wacker Chemie Ag | Novos mutantes de prongf e suas utilizações na produção de beta-ngf |
| US20160220639A1 (en) * | 2013-09-11 | 2016-08-04 | New York University | Methods and compositions for treating bone diseases |
| EP3406259A1 (en) | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
| CN108456681B (zh) * | 2018-03-26 | 2019-10-11 | 江苏中新医药有限公司 | 高效表达重组人神经生长因子的基因组合 |
| WO2019207106A1 (en) | 2018-04-27 | 2019-10-31 | Chiesi Farmaceutici Spa | Production of nerve growth factor (ngf) and of muteins thereof |
| AU2019293579A1 (en) * | 2018-06-29 | 2021-01-07 | The Doshisha | Formulation containing emricasan |
| EP3852785A1 (en) | 2018-09-17 | 2021-07-28 | Chiesi Farmaceutici S.p.A. | Agent for treatment of dermatological disorders |
| IT201900014646A1 (it) * | 2019-08-12 | 2021-02-12 | Consiglio Nazionale Ricerche | Peptide neurotrofico resistente alle proteasi per il trattamento terapeutico di patologie neurodegenerative e/o cutanee |
| MX2022002833A (es) * | 2019-09-17 | 2022-04-06 | Chiesi Farm Spa | Agente para usarse en el tratamiento o prevencion de trastornos oftalmicos. |
| IL302317A (en) | 2020-10-28 | 2023-06-01 | Dompe Farm Spa | Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them |
| EP4039269A1 (en) | 2021-02-05 | 2022-08-10 | Dompe' Farmaceutici S.P.A. | Ngf isoform for use in the treatment of ocular pathologies |
| WO2022221351A1 (en) | 2021-04-13 | 2022-10-20 | Dompé Farmaceutici S.P.A. | Treatment of neuropathic corneal pain with ngf |
| EP4311554A1 (en) | 2022-07-29 | 2024-01-31 | Dompé farmaceutici S.p.a. | Combination for use in ophthalmology |
| EP4316505A1 (en) | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| EP4342485A1 (en) | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4139000A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf |
| ATE257514T1 (de) | 1998-10-09 | 2004-01-15 | Scil Proteins Gmbh | Verfahren zur gewinnung von aktivem beta-ngf |
| US20030040082A1 (en) | 2001-02-16 | 2003-02-27 | Mark Tuszynski | Mutant pro-neurotrophin with improved activity |
| EP1575477B1 (en) | 2001-05-25 | 2012-04-25 | Cornell Research Foundation, Inc. | HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR |
| DE10360483B4 (de) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expressionsvektor und dessen Verwendung |
| WO2005068498A2 (en) | 2004-01-19 | 2005-07-28 | Nsgene A/S | Human therapeutic cells secreting nerve growth factor |
| US20080050776A1 (en) | 2006-05-26 | 2008-02-28 | Kenneth Neet | Stable mutated pro nerve growth factors |
| CN101260398B (zh) | 2007-03-07 | 2013-06-05 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子基因定位改造动物及其制备方法和应用 |
| PT2672984E (pt) | 2011-12-19 | 2015-10-01 | Wacker Chemie Ag | Novos mutantes de prongf e suas utilizações na produção de beta-ngf |
-
2012
- 2012-12-19 PT PT128056959T patent/PT2672984E/pt unknown
- 2012-12-19 EP EP12805695.9A patent/EP2672984B1/en active Active
- 2012-12-19 HU HUE15157320A patent/HUE036265T2/hu unknown
- 2012-12-19 AU AU2012357052A patent/AU2012357052B2/en active Active
- 2012-12-19 CN CN201280062855.6A patent/CN104203264B/zh active Active
- 2012-12-19 KR KR1020167027254A patent/KR20160120788A/ko not_active Application Discontinuation
- 2012-12-19 JP JP2014546588A patent/JP6039146B2/ja active Active
- 2012-12-19 DK DK12805695.9T patent/DK2672984T3/en active
- 2012-12-19 ES ES15157320.1T patent/ES2657344T3/es active Active
- 2012-12-19 RS RS20180159A patent/RS56893B1/sr unknown
- 2012-12-19 PT PT151573201T patent/PT2907521T/pt unknown
- 2012-12-19 MX MX2014007317A patent/MX353074B/es active IP Right Grant
- 2012-12-19 US US14/366,460 patent/US9617322B2/en active Active
- 2012-12-19 SG SG11201402585PA patent/SG11201402585PA/en unknown
- 2012-12-19 TR TR2018/02360T patent/TR201802360T4/tr unknown
- 2012-12-19 KR KR1020147019162A patent/KR101837802B1/ko active IP Right Grant
- 2012-12-19 SI SI201230289T patent/SI2672984T1/sl unknown
- 2012-12-19 CA CA2859262A patent/CA2859262C/en active Active
- 2012-12-19 MX MX2017012894A patent/MX370861B/es unknown
- 2012-12-19 SG SG10201605028VA patent/SG10201605028VA/en unknown
- 2012-12-19 PL PL12805695T patent/PL2672984T3/pl unknown
- 2012-12-19 SI SI201231212T patent/SI2907521T1/en unknown
- 2012-12-19 BR BR112014014913-5A patent/BR112014014913B1/pt active IP Right Grant
- 2012-12-19 CN CN201711352074.1A patent/CN109400693A/zh active Pending
- 2012-12-19 PL PL15157320T patent/PL2907521T3/pl unknown
- 2012-12-19 WO PCT/EP2012/076251 patent/WO2013092776A1/en active Application Filing
- 2012-12-19 EA EA201491155A patent/EA031333B1/ru unknown
- 2012-12-19 ES ES12805695.9T patent/ES2545701T3/es active Active
- 2012-12-19 DK DK15157320.1T patent/DK2907521T3/en active
- 2012-12-19 RS RS20150561A patent/RS54220B1/en unknown
- 2012-12-19 NO NO15157320A patent/NO2907521T3/no unknown
- 2012-12-19 EP EP15157320.1A patent/EP2907521B1/en active Active
- 2012-12-19 HU HUE12805695A patent/HUE027245T2/en unknown
- 2012-12-19 LT LTEP15157320.1T patent/LT2907521T/lt unknown
-
2014
- 2014-05-22 ZA ZA2014/03753A patent/ZA201403753B/en unknown
- 2014-06-15 IL IL233137A patent/IL233137A0/en active IP Right Grant
-
2015
- 2015-03-12 HK HK15102539.7A patent/HK1202055A1/xx unknown
- 2015-08-20 SM SM201500201T patent/SMT201500201B/xx unknown
- 2015-08-26 CY CY20151100747T patent/CY1117016T1/el unknown
- 2015-08-26 HR HRP20150900TT patent/HRP20150900T1/hr unknown
- 2015-12-22 US US14/978,407 patent/US10308694B2/en active Active
-
2016
- 2016-11-03 JP JP2016215749A patent/JP6622683B2/ja active Active
-
2018
- 2018-02-21 HR HRP20180307TT patent/HRP20180307T1/hr unknown
- 2018-02-21 CY CY20181100195T patent/CY1119926T1/el unknown
- 2018-08-07 JP JP2018148261A patent/JP2019011330A/ja active Pending
- 2018-08-08 JP JP2018148957A patent/JP2019006781A/ja active Pending
-
2019
- 2019-04-05 US US16/376,969 patent/US20200031893A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014913A2 (pt) | mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa | |
| BR112012030179A8 (pt) | Polipeptídeo contendo fc | |
| BR112014008529A2 (pt) | il-6 humanizado e receptor de il-6 | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| CR20140141A (es) | Proteinas de funcion dual para el tratamiento de desordenes metabolicos | |
| ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| TN2014000109A1 (en) | Fusion proteins for treating metabolic disorders | |
| BR112015023071A2 (pt) | conjugados de insulina-incretina | |
| GT201300131A (es) | Metodos de tratamiento de trastornos asociados con el fgf21 | |
| UY33222A (es) | Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas | |
| MY156188A (en) | Long - acting formulations of insulins | |
| BR112012027055A2 (pt) | agente estabilizante para proteínas farmacêuticas. | |
| BR112012011305A2 (pt) | uso de uma proteína homóloga a uma proteína meab para aumentar a atividade enzimática de uma mutase do ácido 3-hidroxicarboxílico-coa | |
| BR112013009083A8 (pt) | anticorpos humanos de oncostatin m e métodos de uso | |
| BR112013026976A2 (pt) | alfa glucosidade ácida modificada com processamento acelerado | |
| BR112012017532A2 (pt) | "método para determinar um polipeptídeo com uma sequência de aminoácidos mutante, para produzir um poliptedo e uma imunoglobulina" | |
| BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
| BR112014019328A8 (pt) | Perfil de fenótipo de células progenitoras retinais humanas | |
| EA201290961A1 (ru) | Способы применения растворимого cd24 для лечения ревматоидного артрита | |
| BR112014030440A8 (pt) | método para preparar um alqueno monoinsaturado | |
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| BR112015018265A2 (pt) | Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas | |
| UY30582A1 (es) | Derivados de acido 2-fenoxinicotinico y su uso | |
| BR112015001885A2 (pt) | super agonistas de ação longa de hormônio glicoproteína | |
| BR112013012390A8 (pt) | Hidrolisado de proteína hidrofobizada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2012, OBSERVADAS AS CONDICOES LEGAIS. |